SEC Form 4 · accession 0001209191-17-008365
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin T Conroy
Director
Period of report
Feb 6, 2017
Accepted (ET)
Feb 7, 2017 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.05 | Feb 6, 2017 | A | 25,000 | A | — | Feb 5, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1This option was granted on February 6, 2017 pursuant to the Company's 2013 Stock Incentive Plan with respect to 25,000 shares of Common Stock, with 25% vesting on February 6, 2018 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter and, in the event of a change in control of the Company, the vesting will accelerate in full.